| Trial ID: | L6330 |
| Source ID: | NCT01381887
|
| Associated Drug: |
Placebo
|
| Title: |
A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Placebo|DRUG: Canagliflozin 300mg/Placebo|DRUG: Canagliflozin 300mg/Canagliflozin 150mg|DRUG: Canagliflozin 300mg
|
| Outcome Measures: |
Primary: Plasma concentrations of glucose, Up to Day 44 | Secondary: Rate of insulin secretion, Up to Day 44|Urinary glucose excretion (UGE), Up to Day 44|Renal threshold of glucose excretion (RTG), Up to Day 44|Adverse events, Up to approximately Day 44
|
| Sponsor/Collaborators: |
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
37
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2011-06
|
| Completion Date: |
2011-11
|
| Results First Posted: |
|
| Last Update Posted: |
2013-04-22
|
| Locations: |
Chula Vista, California, United States|Miramar, Florida, United States|Cincinnati, Ohio, United States|Dallas, Texas, United States|San Antonio, Texas, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01381887
|
